BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

Core Insights - BioCryst Pharmaceuticals will present five abstracts on the real-world use of ORLADEYO® (berotralstat) for hereditary angioedema (HAE) at the 2024 AAAAI annual meeting [1] Group 1: Abstract Presentations - The first abstract discusses how berotralstat prophylaxis reduces HAE attack rates regardless of baseline attacks [1] - The second abstract highlights consistently low HAE attack rates with berotralstat, irrespective of prior prophylaxis [1] - The third abstract presents interim analysis from the Berolife Study, assessing the tolerability and effectiveness of berotralstat for long-term prophylaxis [1] - The fourth abstract evaluates adherence to berotralstat through a prospective survey conducted in community pharmacies [1] - The fifth abstract examines the real-world effectiveness of berotralstat in HAE patients with and without C1-inhibitor deficiency [1] Group 2: Product Information - ORLADEYO® (berotralstat) is the first and only oral therapy specifically designed to prevent HAE attacks in patients aged 12 years and older [2] - The drug functions as a plasma kallikrein inhibitor, with one capsule taken daily to prevent HAE attacks [2][3] Group 3: Safety Information - The safety and effectiveness of ORLADEYO for treating acute HAE attacks have not been established, and it should not be used for this purpose [4] - An increase in QT prolongation has been observed at dosages higher than the recommended 150 mg once daily [5] - Common adverse reactions in patients receiving ORLADEYO include abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease [5]